-
-
-
-
-
-
-
Harmony Biosciences forecasts WAKIX revenue to exceed $1 billion in 2026
-
-
-
-
-
-
-
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet
-
-
-
-
-
-
-
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $35 at Mizuho
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Tops Q2 EPS by 20c ; Offers Guidance
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205
-
-
-
-
-
-
-
Harmony Biosciences (HRMY) Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
-
-
-
-
-
-
-
Cantor Fitzgerald Reiterates Overweight Rating on Harmony Biosciences Holdings Inc. (HRMY)
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

